Default company panoramic image

KemPharm, Inc.

KemPharm is a late stage biopharmaceutical company focused on reengineering pain therapies in high value markets to improve abuse potential.

  • Stage Product In Development
  • Industry Biotechnology
  • Location North Liberty, IA, USA
  • Currency USD
  • Employees 12
  • Website

Company Summary

KemPharm focuses on the discovery and development of new chemical entities to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) prodrug approach. KemPharm's most advanced prodrug candidate KP201 (NDA Q2 2014) has the potential to reduce abuse and opioid-induced constipation. KP201's rapid development timeline may allow for a substantial near-term share of the large opioid pain market.


  • Default avatar
    Travis Mickle
    President, CEO

  • Default avatar
    Sven Guenther
    VP Research